Business
ME Therapeutics to Pitch at CSE Capital Tech Connect During Web Summit Vancouver
VANCOUVER, British Columbia, May 07, 2026--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.
About this update from Me Therapeutics Holdings, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":415,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/41643c39be6a131f902ac03805637b7b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2qhAg6rshPajjSRwEwoX1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTgxNQ--/https://media.zenfs.com/en/business-wire.com/41643c39be6a131f902ac03805637b7b","width":415,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vACRvB36b0PDmYdnpE40Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTc0MA--/https://media.zenfs.com/en/business-wire.com/41643c39be6a131f902ac03805637b7b","width":415,"height":480}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 07, 2026--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.","length":474,"tagName":"p"},{"type":"text","content":"During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity.","length":245,"tagName":"p"},{"type":"text","content":"Dr. Dhanji will briefly highlight how ME Therapeutics’s in vivo immune reprogramming approaches represent the next wave of cancer medicines developed to overcome two major challenges preventing anti-cancer immunity: the highly suppressive tumour environment in many solid tumours and the lack of sufficient tumour-specific immune cells. These approaches include targeted expression of key proteins that can overcome the suppressive tumour microenvironment and reprogramming immune cells in vivo with chimeric antigen receptors (CARs) to directly recognize and kill cancer cells. The pitch will cover high-level insights into ME Therapeutics’s science and corporate strategy.","length":674,"tagName":"p"},{"type":"text","content":""It is an honour to be invited by CSE to present our differentiated science, exci...